Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2011

View Archived Issues

Zoonotic paramyxovirus-neutralizing antibody evaluated in nonhuman primates

Promising preclinical data disclosed on new antiobesity therapy

New exportin-1 inhibitors show preclinical potential in MCL and MM

Scientists reveal new potential use for sitagliptin in cord blood transplant

Clinical data reported on PR-104 in leukemia

Intellikine patents new protein kinase inhibitors

Novel guanylyl cyclase activators prepared by Bayer Schering Pharma

Targacept synthesizes novel nicotinic acetylcholine receptor ligands

New metabotropic glutamate mGlu5 receptor positive allosteric modulators reported

FDA grants new approval for Isentress

Novel antibacterial agents designed in Japan

ThromboGenics submits BLA for ocriplasmin

AVEO Pharmaceuticals begins enrollment in tivozanib trial

Roche submits MAA for vismodegib

Japan Tobacco and Gilead Sciences enter licensing agreement

FDA advisory committee sets Qnexa NDA review date

New European approval for Avastin

Repros Therapeutics reports phase IIb data on Androxal

Karo Bio and Pfizer to jointly develop new drugs for autoimmune diseases

Xenome raises funds for development of peptide pain therapy

Ventrus BioSciences completes enrollment in phase III diltiazem trial

ProteoTech and GSK enter agreement

Researchers begin first clinical study of new HIV vaccine

DV-1179 enters proof-of-mechanism trial

Zogenix completes pre-NDA meetings with FDA for Zohydro

Promising phase III data reported on therapy for opioid-induced constipation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal
BioWorld
The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...